Home

ctižádost Váhat Th event free survival overall Tramvaj Rozdělit Plantáž

Wilms tumour event-free and overall survival in Southern and Eastern  Europe: Pooled analyses of clinical data from four childhood cancer  registries (1999–2017) - European Journal of Cancer
Wilms tumour event-free and overall survival in Southern and Eastern Europe: Pooled analyses of clinical data from four childhood cancer registries (1999–2017) - European Journal of Cancer

Kaplan-Meier curve for overall survival (OS) and event-free survival (EFS)  according to the expression of CD30 and IPI.
Kaplan-Meier curve for overall survival (OS) and event-free survival (EFS) according to the expression of CD30 and IPI.

Improved Event-Free Survival and Higher Incidence of Early Fever Associated  with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical  Transplantation - Biology of Blood and Marrow Transplantation
Improved Event-Free Survival and Higher Incidence of Early Fever Associated with Mismatches at HLA-DRB1 after Nonmyeloablative HLA-Haploidentical Transplantation - Biology of Blood and Marrow Transplantation

Progression-free survival (PFS), event-free survival (EFS), and overall...  | Download Scientific Diagram
Progression-free survival (PFS), event-free survival (EFS), and overall... | Download Scientific Diagram

A) Event-free survival (EFS), (B) disease-free survival (DFS), and (C)... |  Download Scientific Diagram
A) Event-free survival (EFS), (B) disease-free survival (DFS), and (C)... | Download Scientific Diagram

Acute myeloid leukemia: survival analysis of patients at a university  hospital of Paraná | Hematology, Transfusion and Cell Therapy
Acute myeloid leukemia: survival analysis of patients at a university hospital of Paraná | Hematology, Transfusion and Cell Therapy

Event-free survival at 24 months is a robust end point for disease-related  outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. |  Semantic Scholar
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. | Semantic Scholar

Non-anthracycline-containing docetaxel and cyclophosphamide regimen is  associated with sustained worse outcome compared with docetaxel,  anthracycline and cyclophosphamide in neoadjuvant treatment of triple  negative and HER2-positive breast cancer ...
Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer ...

OP0294 SJÖGREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND  10-YEAR SURVIVAL | Annals of the Rheumatic Diseases
OP0294 SJÖGREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND 10-YEAR SURVIVAL | Annals of the Rheumatic Diseases

Cancers | Free Full-Text | Anti-GD2 Based Immunotherapy Prevents Late Events  in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis
Cancers | Free Full-Text | Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis

A correlation analysis to assess event-free survival as a trial-level  surrogate for overall survival in early breast cancer - eClinicalMedicine
A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer - eClinicalMedicine

Figure 5. [Event-free survival and overall survival...]. - Wilms Tumor -  NCBI Bookshelf
Figure 5. [Event-free survival and overall survival...]. - Wilms Tumor - NCBI Bookshelf

Kaplan-Meier plot of event-free survival (EFS) and overall survival... |  Download Scientific Diagram
Kaplan-Meier plot of event-free survival (EFS) and overall survival... | Download Scientific Diagram

Event-free Survival with Pembrolizumab in Early Triple-Negative Breast  Cancer | NEJM
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer | NEJM

Relationship between presarcopenia and event occurrence in patients with  primary hepatocellular carcinoma | Scientific Reports
Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma | Scientific Reports

Identification of potential surrogate end points in randomized clinical  trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of  complete response, time-to-event and overall survival end points - Annals  of Oncology
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points - Annals of Oncology

Relationship between event-free survival and overall survival in acute  myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI |  Haematologica
Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI | Haematologica

Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival  as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal  Adenocarcinoma
Frontiers | Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma

Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point,  Is Not a Surrogate for Overall Survival in Men With Localized Prostate  Cancer Treated With Radiation | Journal of Clinical Oncology
Event-Free Survival, a Prostate-Specific Antigen–Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation | Journal of Clinical Oncology

Fig. 72.1, [Four-year event-free survival (EFS), overall...]. - The EBMT  Handbook - NCBI Bookshelf
Fig. 72.1, [Four-year event-free survival (EFS), overall...]. - The EBMT Handbook - NCBI Bookshelf

Identification of potential surrogate end points in randomized clinical  trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of  complete response, time-to-event and overall survival end points - Annals  of Oncology
Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points - Annals of Oncology

Event-free survival and overall survival (A) Event-free survival for... |  Download Scientific Diagram
Event-free survival and overall survival (A) Event-free survival for... | Download Scientific Diagram

Statistical considerations and endpoints for clinical lung cancer studies:  Can progression free survival (PFS) substitute overall survival (OS) as a  valid endpoint in clinical trials for advanced non-small-cell lung cancer?  | Semantic
Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? | Semantic

Event-free survival at 24 months is a robust surrogate endpoint for  long-term survival in pediatric, adolescent, and adult T cell lymphoblastic  lymphoma | SpringerLink
Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma | SpringerLink

Cureus | Does Timing of Completion Radical Cholecystectomy Determine the  Survival Outcome in Incidental Carcinoma Gallbladder: A Single-Center  Retrospective Analysis
Cureus | Does Timing of Completion Radical Cholecystectomy Determine the Survival Outcome in Incidental Carcinoma Gallbladder: A Single-Center Retrospective Analysis